NHS Branded Medicines Tranche Framework for London and South of England
A Contract Award Notice
by NHS ENGLAND
- Source
- Find a Tender
- Type
- Framework (Goods)
- Duration
- not specified
- Value
- £1
- Sector
- HEALTH
- Published
- 20 Aug 2024
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
United Kingdom: Please refer to Document No. 03, Schedule 8 in the ITO Documents for the list of Purchasing Points
1 buyer
- NHS England Leeds
30 suppliers
- Sun Pharma Uxbridge
- Biogen Maidenhead
- Celltrion Healthcare Slough
- Astrazeneca London
- Thornton & Ross Huddersfield
- Glaxosmithkline Brentford
- Novartis Pharmaceuticals London
- Eli Lilly Basingstoke
- Aventis Pharma Reading
- Accord Barnstaple
- Manx Healthcare Warwick
- Chugai Pharma London
- Napp Pharmaceuticals Cambridge
- Drreddys Laboratories Cambridge
- Gedeon Richter London
- Teva Castleford
- Merck Sharpe & Dohme London
- Janssen Cilag High Wycombe
- Organon Pharmaceuticals London
- Thornton & Ross Slaithwaite
- Takeda London
- Pfizer Tadworth
- Zentiva Pharma Guildford
- Roche Products Welwyn Garden City
- Orifarm Brentwood
- Galapagos Biotech Uxbridge
- Leo Pharma Maidenhead
- Biosimilar Collaborations Ireland London
- Sobi Swedish Orphan Biovitrum Abington
- Ucb Pharma Slough
Description
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024Offer reference number: CM/PHR/22/5689CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
Lot Division
| 1 | CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South - Lot 1 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents |
| 2 | CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South - Lot 2 CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents |
| 3 | CM/PHR/22/5689/03 - Omalizumab and Diroximel Fumarate for MAE & NOFE - Lot 3 CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. … Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents |
Award Detail
| 1 | Sun Pharma (Uxbridge)
|
| 2 | Biogen (Maidenhead)
|
| 3 | Celltrion Healthcare (Slough)
|
| 4 | Astrazeneca (London)
|
| 5 | Thornton & Ross (Huddersfield)
|
| 6 | Glaxosmithkline (Brentford)
|
| 7 | Novartis Pharmaceuticals (London)
|
| 8 | Eli Lilly (Basingstoke)
|
| 9 | Aventis Pharma (Reading)
|
| 10 | Accord (Barnstaple)
|
| 11 | Manx Healthcare (Warwick)
|
| 12 | Chugai Pharma (London)
|
| 13 | Napp Pharmaceuticals (Cambridge)
|
| 14 | Drreddys Laboratories (Cambridge)
|
| 15 | Gedeon Richter (London)
|
| 16 | Teva (Castleford)
|
| 17 | Merck Sharpe & Dohme (London)
|
| 18 | Celltrion Healthcare (Slough)
|
| 19 | Janssen Cilag (High Wycombe)
|
| 20 | Organon Pharmaceuticals (London)
|
| 21 | Thornton & Ross (Slaithwaite)
|
| 22 | Glaxosmithkline (Brentford)
|
| 23 | Takeda (London)
|
| 24 | Pfizer (Tadworth)
|
| 25 | Zentiva Pharma (Guildford)
|
| 26 | Roche Products (Welwyn Garden City)
|
| 27 | Eli Lilly (Basingstoke)
|
| 28 | Aventis Pharma (Reading)
|
| 29 | Accord (Barnstaple)
|
| 30 | Orifarm (Brentwood)
|
| 31 | Galapagos Biotech (Uxbridge)
|
| 32 | Drreddys Laboratories (Cambridge)
|
| 33 | Leo Pharma (Maidenhead)
|
| 34 | Biosimilar Collaborations Ireland (London)
|
| 35 | Sobi Swedish Orphan Biovitrum (Abington)
|
| 36 | Ucb Pharma (Slough)
|
| 37 | Biogen (Maidenhead)
|
| 38 | Celltrion Healthcare (Slough)
|
| 39 | Novartis Pharmaceuticals (London)
|
Renewal Options
Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months
Award Criteria
| price | _ |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Options are available.
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. **
Reference
- ocds-h6vhtk-0445bc
- FTS 026491-2024